Bristol-Myers Squibb [BMY] vs Gilead Sciences [GILD] Detailed Stock Comparison
Bristol-Myers Squibb
NYSE
Loading...
Gilead Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Bristol-Myers Squibb wins in 8 metrics, Gilead Sciences wins in 11 metrics, with 0 ties. Gilead Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bristol-Myers Squibb | Gilead Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 18.00 | 24.06 | Bristol-Myers Squibb |
| Price-to-Book Ratio | 5.23 | 7.44 | Bristol-Myers Squibb |
| Debt-to-Equity Ratio | 291.55 | 130.79 | Gilead Sciences |
| PEG Ratio | 6.38 | 15.41 | Bristol-Myers Squibb |
| EV/EBITDA | 6.73 | 11.56 | Bristol-Myers Squibb |
| Profit Margin (TTM) | 10.58% | 20.76% | Gilead Sciences |
| Operating Margin (TTM) | 33.66% | 38.49% | Gilead Sciences |
| EBITDA Margin (TTM) | 33.66% | 38.49% | Gilead Sciences |
| Return on Equity | 29.32% | 32.65% | Gilead Sciences |
| Return on Assets (TTM) | 8.34% | 12.14% | Gilead Sciences |
| Free Cash Flow (TTM) | $13.94B | $10.31B | Bristol-Myers Squibb |
| Dividend Yield | N/A | 2.84% | N/A |
| 1-Year Return | -2.91% | 49.71% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 1.91 | 4.96 | Bristol-Myers Squibb |
| Enterprise Value | $128.67B | $158.60B | Gilead Sciences |
| EV/Revenue Ratio | 2.70 | 5.52 | Bristol-Myers Squibb |
| Gross Profit Margin (TTM) | 72.52% | 76.90% | Gilead Sciences |
| Revenue per Share (TTM) | $23 | $23 | Bristol-Myers Squibb |
| Earnings per Share (Diluted) | $2.49 | $4.76 | Gilead Sciences |
| Beta (Stock Volatility) | 0.37 | 0.35 | Gilead Sciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Bristol-Myers Squibb vs Gilead Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | 1.30% | 4.73% | -2.43% | -4.75% | -20.21% | -20.13% |
| Gilead Sciences | 8.27% | -1.79% | -1.34% | 11.51% | 14.83% | 20.03% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | -2.91% | -39.98% | -28.18% | -28.09% | 72.34% | 81.44% |
| Gilead Sciences | 49.71% | 75.16% | 60.99% | -4.60% | 542.66% | 940.38% |
Performance & Financial Health Analysis: Bristol-Myers Squibb vs Gilead Sciences
| Metric | BMY | GILD |
|---|---|---|
| Market Information | ||
| Market Cap | $91.23B | $142.44B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 15,287,550 | 5,751,080 |
| 90 Day Avg. Volume | 13,552,280 | 6,288,790 |
| Last Close | $45.95 | $119.40 |
| 52 Week Range | $42.96 - $63.33 | $72.43 - $121.38 |
| % from 52W High | -27.44% | -1.63% |
| All-Time High | $81.44 (Nov 28, 2022) | $123.37 (Jun 22, 2015) |
| % from All-Time High | -43.58% | -3.22% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.01% | 0.00% |
| Quarterly Earnings Growth | -0.22% | 0.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.21% |
| Operating Margin (TTM) | 0.34% | 0.38% |
| Return on Equity (TTM) | 0.29% | 0.33% |
| Debt to Equity (MRQ) | 291.55 | 130.79 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $8.57 | $15.39 |
| Cash per Share (MRQ) | $6.68 | $7.00 |
| Operating Cash Flow (TTM) | $15.90B | $10.37B |
| Levered Free Cash Flow (TTM) | $16.02B | $9.99B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 2.84% |
| Last 12-Month Dividend | N/A | $3.12 |
Valuation & Enterprise Metrics Analysis: Bristol-Myers Squibb vs Gilead Sciences
| Metric | BMY | GILD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 18.00 | 24.06 |
| Forward P/E | 6.38 | 15.41 |
| PEG Ratio | 6.38 | 15.41 |
| Price to Sales (TTM) | 1.91 | 4.96 |
| Price to Book (MRQ) | 5.23 | 7.44 |
| Market Capitalization | ||
| Market Capitalization | $91.23B | $142.44B |
| Enterprise Value | $128.67B | $158.60B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.70 | 5.52 |
| Enterprise to EBITDA | 6.73 | 11.56 |
| Risk & Other Metrics | ||
| Beta | 0.37 | 0.35 |
| Book Value per Share (MRQ) | $8.57 | $15.39 |
Financial Statements Comparison: Bristol-Myers Squibb vs Gilead Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BMY | GILD |
|---|---|---|
| Revenue/Sales | $12.27B | $6.67B |
| Cost of Goods Sold | $3.37B | $1.54B |
| Gross Profit | $8.90B | $5.13B |
| Research & Development | $2.58B | $1.38B |
| Operating Income (EBIT) | $3.77B | $2.49B |
| EBITDA | $5.26B | $3.28B |
| Pre-Tax Income | $1.77B | $1.65B |
| Income Tax | $460.00M | $334.00M |
| Net Income (Profit) | $1.31B | $1.32B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BMY | GILD |
|---|---|---|
| Cash & Equivalents | $10.88B | $7.93B |
| Total Current Assets | $30.78B | $16.90B |
| Total Current Liabilities | $24.07B | $12.34B |
| Long-Term Debt | $47.51B | $22.15B |
| Total Shareholders Equity | $17.45B | $19.08B |
| Retained Earnings | $16.11B | $10.93B |
| Property, Plant & Equipment | $1.22B | $7.96B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BMY | GILD |
|---|---|---|
| Operating Cash Flow | $2.11B | $1.56B |
| Capital Expenditures | N/A | $-104.00M |
| Free Cash Flow | $1.69B | $1.65B |
| Debt Repayment | N/A | $-1.76B |
| Common Stock Repurchase | N/A | $-730.00M |
Short Interest & Institutional Ownership Analysis
| Metric | BMY | GILD |
|---|---|---|
| Shares Short | 38.38M | 22.54M |
| Short Ratio | 2.58 | 2.80 |
| Short % of Float | 0.02% | 0.02% |
| Average Daily Volume (10 Day) | 15,287,550 | 5,751,080 |
| Average Daily Volume (90 Day) | 13,552,280 | 6,288,790 |
| Shares Outstanding | 2.03B | 1.25B |
| Float Shares | 2.03B | 1.24B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.82% | 0.90% |
Dividend Analysis & Yield Comparison: Bristol-Myers Squibb vs Gilead Sciences
| Metric | BMY | GILD |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.12 |
| Last 12-Month Dividend Yield | N/A | 2.84% |
| 3-Year Avg Annual Dividend | N/A | $3.04 |
| 3-Year Avg Dividend Yield | N/A | 0.93% |
| 3-Year Total Dividends | N/A | $9.12 |
| Ex-Dividend Date | N/A | Jun 13, 2025 |